# EDGAR Filing Document

**Accession Number:** 0001798749
**File Stem:** 0000000000-25-011803
**Filing Date:** 2025-12
**Character Count:** 2338
**Document Hash:** 13f913637e27eb979a3def01aae991f0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-011803.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0000000000-25-011803

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251223

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jade Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001798749
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831377888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-292369

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** (781) 312-3013

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerovate Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200103
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-328848

## Text-Extract

```

                                                           December 23, 2025

Tom Frohlich
Chief Executive Officer
Jade Biosciences, Inc.
221 Crescent St., Building 23
Suite 105
Waltham, MA 02453

       Re: Jade Biosciences, Inc.
           Registration Statement on Form S-1
           Filed December 22, 2025
           File No. 333-292369
Dear Tom Frohlich:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tim Buchmiller at 202-551-3635 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Anthony Gostanian, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._